The American Society of Gene & Cell Therapy (ASGCT) is the primary membership organization for scientists, physicians, professionals, and patient advocates involved in gene and cell therapy. ASGCT serves as a catalyst to transform medicine by advancing gene and cell therapies to benefit patients and society.
1996
91-1766321
$20.49 million

An annual gathering of leaders in gene and cell therapy to share research and advancements.

The leading journal for gene and cell therapy research, publishing peer-reviewed research and reviews.

Access extensive resources, including landscape reports, podcasts, and the ASGCT blog.

November 19-20, 2024
An event focusing on advancements in the treatment of muscular dystrophy.
Learn MoreOverall Score
71
58
/100
Program Expense Ratio
81.88%
14
/20
Program Revenue Growth
37.00%
18
/20
Leverage Ratio
0.306
12
/20
Working Capital Ratio
1.297
12
/20
Fundraising Efficiency
0
2
/20
Fiscal Year:2022
Source:Source: Self-reported by organization
| Category | Amount | Percentage |
|---|---|---|
| Contributions, Gifts, and Grants | 721.9K | 5.78% |
| Program Services | 11.56M | 92.59% |
| Investment Income | 121.6K | 0.97% |
| Sales of Non-Inventory Assets | 0 | 0.00% |
| Other Notable Sources | 81.24K | 0.65% |
| Total Revenue | 12.48M | 100.00% |
Med Research
Hereditary Disease ResearchMed Research
Hereditary Disease ResearchMed Research
Hereditary Disease ResearchMed Research
Hereditary Disease ResearchMed Research
Hereditary Disease Research